Opioid-induced constipation: Pathophysiology, clinical consequences, and management

Gastroenterology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Kumar, Lalit ^a   Barker, Chris ^b,c   Emmanuel, Anton ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c SOUTHPORT AND ORMSKIRK HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; LAXATIVE; LUBIPROSTONE; NALOXONE; OPIATE; PLACEBO;

ANALGESIA; COMPARATIVE STUDY; CONSTIPATION; DIETARY FIBER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FLUID INTAKE; HUMAN; LIFESTYLE MODIFICATION; OPIOID INDUCED CONSTIPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

EID: 84901776204     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2014/141737     Document Type: Review

References (41)

1. Casati A., Sedefov R., Pfeiffer-Gerschel T., Misuse of medicines in the European Union: a systematic review of the literature. European Addiction Research 2012 18 228 245
2. Alexander G., Kruszewski S. P., Webster D. W., Rethinking opioid prescribing to protect patient safety and public health. Journal of the American Medical Association 2012 308 1865 1866
3. NICE, Opioids in Palliative Care: Safe and Effective Prescribing of Strong Opioids for Pain in Palliative Care of Adults Clinical Guideline 140 2012 London, UK NICE
4. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C., Functional Bowel Disorders. Gastroenterology 2006 130 5 1480 1491 2-s2.0-33646201684 10.1053/j.gastro.2005.11.061
5. Ueberall M. A., Müller-Lissner S., Buschmann-Kramm C., Bosse B., The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non- constipated population of pain patients. Journal of International Medical Research 2011 39 1 41 50 2-s2.0-79952946751
6. Rentz A. M., Yu R., Müller-Lissner S., Leyendecker P., Validation of the Bowel Function index to detect clinically meaningful changes in opioid-induced constipation. Journal of Medical Economics 2009 12 4 371 383 2-s2.0-72749092412 10.3111/13696990903430481
7. McMillan S. C., Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004 11 3, supplement 1 3 9 2-s2.0-2942567782 (Pubitemid 38756665)
8. Benyamin R., Trescot A. M., Datta S., Buenaventura R., Adlaka R., Sehgal N., Glaser S. E., Vallejo R., Opioid complications and side effects. Pain Physician 2008 11 2 S105 S120 2-s2.0-43649086220 (Pubitemid 351682081)
9. Holzer P., Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neuroscience Letters 2004 361 1-3 192 195 2-s2.0-2342594524 10.1016/j.neulet.2003.12.004 (Pubitemid 38609249)
10. Mancini I., Bruera E., Constipation in advanced cancer patients. Supportive Care in Cancer 1998 6 4 356 364 2-s2.0-0031871290 10.1007/s005200050177 (Pubitemid 28337126)
11. Kalso E., Edwards J. E., Moore R. A., McQuay H. J., Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004 112 3 372 380 2-s2.0-9244233833 10.1016/j.pain.2004.09.019 (Pubitemid 39550738)
12. Panchal S. J., Müller-Schwefe P., Wurzelmann J. I., Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. International Journal of Clinical Practice 2007 61 7 1181 1187 2-s2.0-34250617568 10.1111/j.1742-1241.2007.01415.x (Pubitemid 46934629)
13. Pappagallo M., Incidence, prevalence, and management of opioid bowel dysfunction. The American Journal of Surgery 2001 182 5 11S 18S 2-s2.0-0035695398 (Pubitemid 34072942)
14. Thorpe D. M., Management of opioid-induced constipation. Current pain and headache reports 2001 5 3 237 240 2-s2.0-0035377188
15. Wald A., Management and prevention of fecal impaction. Current Gastroenterology Reports 2008 10 5 499 501 2-s2.0-58149352724 10.1007/s11894-008-0091-y
16. Devulder J., Richarz U., Nataraja S. H., Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Current Medical Research and Opinion 2005 21 10 1555 1566 2-s2.0-27144447123 10.1185/030079905X65321 (Pubitemid 41505022)
17. Bell T., Annunziata K., Leslie J. B., Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. Journal of Opioid Management 2009 5 3 137 144 2-s2.0-68349085606
18. Holmes S., Use of a modified symptom distress scale in assessment of the cancer patient. International Journal of Nursing Studies 1989 26 1 69 79 2-s2.0-0024583209
19. Kurz A., Sessler D. I., Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003 63 7 649 671 2-s2.0-0037249711 10.2165/00003495-200363070-00003 (Pubitemid 36408072)
20. Müller-Lissner S. A., Kamm M. A., Scarpignato C., Wald A., Myths and misconceptions about chronic constipation. The American Journal of Gastroenterology 2005 100 1 232 242 2-s2.0-13744263848 10.1111/j.1572-0241.2005. 40885.x (Pubitemid 41623292)
21. Goodheart C., Leavitt S., Managing Opioid-Induced Constipation in Ambulatory-Care Patients 2006 Glenview, Ill, USA Pain Treatment Topics
22. Freedman M. D., Schwartz H. J., Roby R., Fleisher S., Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. The Journal of Clinical Pharmacology 1997 37 10 904 907 2-s2.0-0030781311 (Pubitemid 27514908)
23. Ramkumar D., Rao S. S. C., Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. The American Journal of Gastroenterology 2005 100 4 936 971 2-s2.0-17544361897 10.1111/j.1572-0241.2005. 40925.x (Pubitemid 40592390)
24. Ford A. C., Suares N. C., Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011 60 2 209 218 2-s2.0-78651086264 10.1136/gut.2010.227132
25. Candy B., Jones L., Goodman M. L., Drake R., Tookman A., Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2011 1 CD003448 2-s2.0-79952271850
26. Ahmedzai S. H., Nauck F., Bar-Sela G., Bosse B., Leyendecker P., Hopp M., A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine 2012 26 1 50 60 2-s2.0-84555195765 10.1177/0269216311418869
27. Thomas J., Karver S., Cooney G. A., Chamberlain B. H., Watt C. K., Slatkin N. E., Stambler N., Kremer A. B., Israel R. J., Methylnaltrexone for opioid-induced constipation in advanced illness. The New England Journal of Medicine 2008 358 22 2332 2343 2-s2.0-44349145194 10.1056/NEJMoa0707377 (Pubitemid 351749157)
28. Relistor [package insert],. Wyeth Pharmaceuticals, Philadelphia, Pa, USA, 2009
29. Simpson K., Leyendecker P., Hopp M., Müller-Lissner S., Löwenstein O., De Andrés J., Troy Ferrarons J., Bosse B., Krain B., Nichols T., Kremers W., Reimer K., Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Current Medical Research and Opinion 2008 24 12 3503 3512 2-s2.0-62349085314 10.1185/03007990802584454
30. Vondrackova D., Leyendecker P., Meissner W., Hopp M., Szombati I., Hermanns K., Ruckes C., Weber S., Grothe B., Fleischer W., Reimer K., Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Journal of Pain 2008 9 12 1144 1154 2-s2.0-56349136276 10.1016/j.jpain.2008.06.014
31. Sandner-Kiesling A., Leyendecker P., Hopp M., Tarau L., Lejcko J., Meissner W., Sevcik P., Hakl M., Hrib R., Uhl R., Dürr H., Reimer K., Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. International Journal of Clinical Practice 2010 64 6 763 774 2-s2.0-77950641718 10.1111/j.1742-1241.2010. 02360.x
32. Löwenstein O., Leyendecker P., Hopp M., Schutter U., Rogers P. D., Uhl R., Bond S., Kremers W., Nichols T., Krain B., Reimer K., Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opinion on Pharmacotherapy 2009 10 4 531 543 2-s2.0-65649126026 10.1517/14656560902796798
33. Meissner W., Leyendecker P., Mueller-Lissner S., Nadstawek J., Hopp M., Ruckes C., Wirz S., Fleischer W., Reimer K., A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. European Journal of Pain 2009 13 1 56 64 2-s2.0-58149178876 10.1016/j.ejpain.2008.06.012
34. Schmidt W. K., Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. The American Journal of Surgery 2001 182 5 S27 S38 2-s2.0-0035543168
35. Webster L., Jansen J. P., Peppin J., Lasko B., Irving G., Morlion B., Snidow J., Pierce A., Mortensen E., Kleoudis C., Carter E., Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008 137 2 428 440 2-s2.0-45549109284 10.1016/j.pain.2007. 11.008
36. Irving G., Pénzes J., Ramjattan B., Cousins M., Rauck R., Spierings E. L. H., Kleoudis C. S., Snidow J. W., Pierce A., Wurzelmann J., Mortensen E. R., A randomized, placebo-controlled phase 3 trial (study sb-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. Journal of Pain 2011 12 2 175 184 2-s2.0-79551599018 10.1016/j.jpain.2010.06.013
37. Moss J., Rosow C. E., Development of peripheral opioid antagonists: new insights into opioid effects. Mayo Clinic Proceedings 2008 83 10 1116 1130 2-s2.0-54049153194 10.4065/83.10.1116
38. Adolor Corporation,. 2008, http://phx.corporate-ir.net/phoenix.zhtml?c= 120919&p=irol-newsArticle&ID=1237524&highlight=
39. Wong B. S., Camilleri M., Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opinion on Pharmacotherapy 2011 12 6 983 990 2-s2.0-79952767341 10.1517/14656566.2011.566559
40. Sucampo Pharmaceuticals,. http://investor.sucampo.com/phoenix.zhtml?c= 201197&p=irol-newsArticle&ID=1309679&highlight
41. Ford A. C., Brenner D. M., Schoenfeld P. S., Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. The American Journal of Gastroenterology 2013 108 1566 1574